Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-Resistant Fallopian Tube Carcinoma”

173 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 173 results

Large-scale testing (Phase 3)Ended earlyNCT02641639
What this trial is testing

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

Who this might be right for
Platinum Resistant Ovarian Cancer
Mateon Therapeutics 70
Testing effectiveness (Phase 2)Study completedNCT01402271
What this trial is testing

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
European Organisation for Research and Treatment of Cancer - EORTC 88
Large-scale testing (Phase 3)Looking for participantsNCT07604766
What this trial is testing

An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

Who this might be right for
Platinum-resistant Ovarian Cancer
Genmab 82
Testing effectiveness (Phase 2)UnknownNCT04375956
What this trial is testing

Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients

Who this might be right for
Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Testing effectiveness (Phase 2)Ended earlyNCT02900560
What this trial is testing

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

Who this might be right for
Epithelial Ovarian Cancer
Translational Research in Oncology 34
Testing effectiveness (Phase 2)Study completedNCT03161132
What this trial is testing

Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin

Who this might be right for
Advanced Ovarian Cancer
Grupo Español de Investigación en Cáncer de Ovario 32
Early research (Phase 1)UnknownNCT04029909
What this trial is testing

A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Who this might be right for
Ovarian Epithelial CancerFallopian Tube CancerPrimary Peritoneal Cancer
Lee's Pharmaceutical Limited 12
Testing effectiveness (Phase 2)Study completedNCT03026062
What this trial is testing

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
M.D. Anderson Cancer Center 100
Testing effectiveness (Phase 2)WithdrawnNCT06393751
What this trial is testing

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+20 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Ended earlyNCT05092360
What this trial is testing

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

Who this might be right for
Platinum-resistant Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Mural Oncology, Inc 456
Testing effectiveness (Phase 2)Ended earlyNCT00085384
What this trial is testing

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT00993616
What this trial is testing

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Who this might be right for
Brenner TumorFallopian Tube CancerOvarian Clear Cell Cystadenocarcinoma+7 more
National Cancer Institute (NCI) 29
Testing effectiveness (Phase 2)UnknownNCT04846842
What this trial is testing

Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Lee's Pharmaceutical Limited 46
Testing effectiveness (Phase 2)WithdrawnNCT02948101
What this trial is testing

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
M.D. Anderson Cancer Center
Early research (Phase 1)Active Not RecruitingNCT01883297
What this trial is testing

"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
RecurrentPlatinum-resistantHigh Grade Serous Ovarian Cancer+2 more
University Health Network, Toronto 3
Early research (Phase 1)Looking for participantsNCT07489287
What this trial is testing

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer
Roswell Park Cancer Institute 18
Large-scale testing (Phase 3)Study completedNCT01204749
What this trial is testing

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
Amgen 919
Large-scale testing (Phase 3)UnknownNCT05043402
What this trial is testing

Navicixizumab in Patients With Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
OncXerna Theraputics, Inc. 400
Early research (Phase 1)Active Not RecruitingNCT05691504
What this trial is testing

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Who this might be right for
Advanced Endometrial CarcinomaMetastatic Endometrial CarcinomaMetastatic Fallopian Tube Carcinoma+8 more
National Cancer Institute (NCI) 42
Next Page